|
|
Article: Genaera Corporation Presents Clinical Results for EVIZON(TM) for Treatment of Age-Related Macular Degeneration at the Annual ASRS Meeting.
- Article from:
- PR Newswire
- Article date:
- July 18, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PLYMOUTH MEETING, Pa., July 18 /PRNewswire-FirstCall/ -- Genaera Corporation today announced the presentation of clinical trial results from two U.S. Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of choroidal neovascularization associated with age-related macular degeneration (AMD), also known as "wet" AMD. EVIZON is the leading systemically delivered anti-angiogenic drug being developed to treat AMD. The presentations were held at the 23rd Annual Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Quebec, Canada.
Brian P. Connolly, MD, Retina Research Services, Wills Eye Hospital, Philadelphia, ...